Compare the Effect of INS Alone and Added LTRA in Treatment of SAR
Status:
Completed
Trial end date:
2016-09-30
Target enrollment:
Participant gender:
Summary
It is not proven unequivocally whether a combination of an intranasal corticosteroids (INS)
and a cysteinyl leukotriene receptor antagonist has greater efficacy than INS in the
treatment of severe allergic rhinitis (AR) . We performed a randomized, open-label study in
46 seasonal AR subjects receiving budesonide (BD, 256ug) plus montelukast (MNT, 10 mg) or BD
alone (256ug) for 2 weeks. Visual analog scale (VAS) scores, nasal cavity volume (NCV), nasal
airway resistance (NAR) and fractional exhaled nitric oxide (FeNO) were assessed before and
at end of treatments as the primary treatment outcomes. Similarly, histamine, eosinophil
cationic protein (ECP) and cysteinyl-leukotrienes (Cyslts) in nasal secretion and Th1/Th2
cells in nasal mucosa were evaluated as the secondary treatment outcomes.